- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05172518
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
December 27, 2021 updated by: wang shusen, Sun Yat-sen University
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer : A Phase III, Open-label, Randomized Controlled Trial
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.
Study Overview
Status
Not yet recruiting
Study Type
Interventional
Enrollment (Anticipated)
512
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: shusen wang, MD
- Phone Number: +86-13926168469
- Email: wangshs@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Shusen Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Signed Informed Consent Form;
- Women aged ≥ 18 years;
- Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
- The primary tumor and metastases (if aspirated) are both HER2-negative;
- Eastern Cooperative Oncology Group (ECOG) score [0-2] points;
- Measurable disease according to RECIST version 1.1;
- Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomisation;
- No more than one prior chemotherapy regimen for inoperable locally advanced or metastatic HER2-negative breast cancer;
- Hormone receptor positive patients are allowed no more than two lines of prior endocrine therapy for metastatic disease (including CDK4/6 inhibitors, chidamide and PI3K inhibitors, etc.);
- Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia are allowed ;
Patients with asymptomatic CNS metastases may be enrolled, if:
- Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or
- Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;
- Adequate hematological, hepatic and renal function;
- Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;
- Life expectancy of at least 12 weeks;
- Patients must be able to participate and comply with treatment and follow-up.
Exclusion Criteria:
- HER-2 positive (IHC + + +, or FISH positive);
- Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
- Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, hormone therapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
- Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
- Symptomatic peripheral neuropathy or CTCAE 5.0 grade ≥ 2;
- Experienced grade 3 or above nervous system-related adverse events after treatment with anti-microtubule drugs;
- Received taxane and/or capecitabine-containing adjuvant/neoadjuvant chemotherapy within 1 year prior to the first study treatment;
- Received prior first-line chemotherapy containing a taxane or capecitabine;
- Symptomatic central nervous system metastases;
- Inability to take or absorb oral medications;
- Pregnant or lactating women;
- Known or suspected hypersensitivity to any of the study drugs or excipients;
- Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ;
- Any other condition that the investigator considers inappropriate to participate in this trial .
- Use of corticosteroids is prohibited.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
Taxane plus Intermittent Capecitabine
|
Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first.
Each cycle is 3 weeks in duration.
|
Experimental: Arm B
Utidelone plus Intermittent Capecitabine
|
Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first.
Each cycle is 3 weeks in duration.
|
Active Comparator: Arm C
Taxane plus Metronomic Capecitabine
|
Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(For the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first.
Each cycle is 3 weeks in duration.
|
Experimental: Arm D
Utidelone plus Metronomic Capecitabine
|
Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 ~8 cycles(for the the patients with SD, PR or CR after 6~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first.
Each cycle is 3 weeks in duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: up to 60 months
|
Time from randomization to progression or death (whichever occurred first).
|
up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: up to 60 months
|
The proportion of patients with a best response of CR or PR, according to RECIST 1.1 criteria.
|
up to 60 months
|
Time to response (TTR)
Time Frame: up to 60 months
|
the time from randomization to the first documentation of disease response (CR or PR).
|
up to 60 months
|
Duration of response (DOR)
Time Frame: up to 60 months
|
the time from the first evaluation that criteria for CR or PR are met until PD or death is observed, whichever occurs first, calculated only for patients whose best response is evaluated as CR or PR.
|
up to 60 months
|
Overall survival (OS)
Time Frame: up to 60 months
|
Time from randomization to death Time from randomization to death Time from randomization to death Time from randomization to death.
|
up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2022
Primary Completion (Anticipated)
March 1, 2027
Study Completion (Anticipated)
March 1, 2030
Study Registration Dates
First Submitted
December 27, 2021
First Submitted That Met QC Criteria
December 27, 2021
First Posted (Actual)
December 29, 2021
Study Record Updates
Last Update Posted (Actual)
December 29, 2021
Last Update Submitted That Met QC Criteria
December 27, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYSU-2021-UCAN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
Clinical Trials on Taxane plus Intermittent Capecitabine
-
Yonsei UniversityRecruitingBreast CancerKorea, Republic of
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Northumbria UniversityCompletedBody Weight ChangesUnited Kingdom
-
Hoffmann-La RocheCompletedBreast CancerUnited Kingdom, Spain, Australia, Sweden
-
Ruijin HospitalRecruitingHER2-negative Advanced Gastric CancerChina
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingCancer | Metastatic | Breast | Triple Negative | Disseminated Tumor CellUnited States
-
Nanfang Hospital, Southern Medical UniversityNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHER2 Positive Metastatic Breast CancerChina
-
Fudan UniversityRecruitingLocally Advanced Colon CancerChina